<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234182</url>
  </required_header>
  <id_info>
    <org_study_id>EC 1018-98</org_study_id>
    <nct_id>NCT00234182</nct_id>
  </id_info>
  <brief_title>Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC</brief_title>
  <official_title>Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of Hepatocellular Carcinoma: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <brief_summary>
    <textblock>
      We conducted a randomized controlled trial of adjuvant interferon therapy in patients with&#xD;
      predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the&#xD;
      prognosis after hepatic resection could be improved. Since February 1999, patients with no&#xD;
      residual disease after hepatic resection for HCC were randomly assigned with stratification&#xD;
      by pTNM stage to receive no treatment (control group), interferon alpha-2b 10 MIU/m2 (IFN-I&#xD;
      group) or 30 MIU/m2 (IFN-II group) thrice weekly for 16 weeks. Enrollment to the IFN-II group&#xD;
      was terminated from January 2000 because adverse effects resulted in treatment&#xD;
      discontinuation in the first 6 patients. By June 2002, 40 patients each had been enrolled&#xD;
      into the control group and IFN-I group. The baseline clinical, laboratory and tumor&#xD;
      characteristics of both groups were comparable. The 1- and 5-year survival rates were 85% and&#xD;
      61%, respectively for the control group and 97% and 79%, respectively for the IFN-I group&#xD;
      (P=0.137). After adjusting for the confounding prognostic factors in a Cox model, the&#xD;
      relative risk of death for interferon treatment was 0.42 (95% CI 0.17 - 1.05; P=0.063).&#xD;
      Exploratory subset analysis showed that adjuvant interferon had no survival benefit for pTNM&#xD;
      stage I/II tumor (5-year survival 90% in both groups; P=0.917) but prevented early recurrence&#xD;
      and improved the 5-year survival of patients with stage III/IVA tumor from 24% to 68%&#xD;
      (P=0.038). In conclusion, in a group of patients with predominantly hepatitis B-related HCC,&#xD;
      adjuvant interferon therapy prevented early recurrence and improved survival in those with&#xD;
      pTNM stage III/IVA tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Background&#xD;
&#xD;
           Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death in Hong&#xD;
           Kong and the majority are hepatitis B related. Hepatic resection has remained the only&#xD;
           therapeutic option that can offer these patients a chance of long-term survival.&#xD;
           Although the safety of hepatectomy has improved, postoperative recurrences are frequent.&#xD;
           Depending on the size of the primary tumors, recent reports from Japan, France and Hong&#xD;
           Kong1 showed that the postoperative recurrence rate was 20 to 64% at one year and 57 to&#xD;
           81% at 3 years.&#xD;
&#xD;
           While the hepatic remnant is the predominant site of recurrence, involvement of&#xD;
           extrahepatic organs was not infrequent. There are three possible mechanisms for the&#xD;
           development of recurrent disease:&#xD;
&#xD;
           i) residual tumor cells due to an inadequate resection margin ii) subclinical metastasis&#xD;
           that occurs before or during hepatic resection iii) metachronous multicentric&#xD;
           hepatocarcinogenesis which may be related to the underlying necroinflammation of chronic&#xD;
           active hepatitis and oncogenic activities of hepatitis viruses.&#xD;
&#xD;
           The surgeon's attempt to prevent recurrence by more extensive resection is prohibited by&#xD;
           the need to preserve hepatic function. Futhermore, even a major hepatic resection cannot&#xD;
           guarantee freedom from recurrence since metachronous multicentric tumors can develop in&#xD;
           the entire liver. Theorectically, total hepatectomy and liver transplantation removes&#xD;
           both the subclinical metastases in the liver and prevent metachronous lesions.&#xD;
           Unfortunately, with immunosuppressive therapy, recurrences are frequent and tumors grow&#xD;
           more rapidly, thus, illustrating the importance of the host immune surveillance in&#xD;
           preventing the development of recurrence.&#xD;
&#xD;
           The use of postoperative regional and systemic chemotherapy has been reported. Although&#xD;
           retrospective studies have shown encouraging results, there are only limited number of&#xD;
           prospective trials. The favourable result of the use of oral&#xD;
           1-hexylcarbomyl-5-fluorouracil in a multi-center trial as reported by Yamamoto and&#xD;
           colleagues was questionable since treatment was suspended due to side-effects in 44% of&#xD;
           the patients. Our single-center prospective randomised study performed at Queen Mary&#xD;
           Hospital (QMH) using a combination of transarterial chemoembolisation and systemic&#xD;
           epirubicin showed a higher extrahepatic recurrence rate and worse outcome with the use&#xD;
           of adjuvant chemotherapy. The reasons for the failure of adjuvant chemotherapy include:&#xD;
&#xD;
           i) HCC is slow-growing and hence cytotoxic drug resistant. ii) the associated liver&#xD;
           cirrhosis limits the maximum tolerated intensity of chemotherapy iii) the anticancer&#xD;
           agents may adversely affect the host immunity&#xD;
&#xD;
        2. Interferon alpha-2b&#xD;
&#xD;
           Interferon alpha-2b is a recombinant form of human interferon. Interferons are cytokines&#xD;
           possessing anti-viral, anti-proliferative and immunodulatory effects. Interferon may&#xD;
           halt the replication of both hepatitis B and hepatitis C virus, thus, reducing the&#xD;
           severity of the chronic active hepatitis. The histologic activity of chronic active&#xD;
           hepatitis is an important risk factor for recurrence related to metachronous&#xD;
           multicentric hepatocarcinogenesis and the use of interferon has been shown to reduce the&#xD;
           incidence of HCC in patients with cirrhosis due to hepatitis C and possibly hepatitis B.&#xD;
&#xD;
           Interferon has a powerful anti-proliferative effect on hepatoma cell-line PLC/PRF/5 in a&#xD;
           dose-dependent manner both in-vitro and in-vivo. The use of interferon has been applied&#xD;
           to patients with inoperable HCC with a tumour regression rate and survival rate superior&#xD;
           to that of placebo-control or chemotherapeutic agents such as doxorubicin.&#xD;
&#xD;
           Peripheral blood mononuclear cells from patients with HCC have considerably reduced&#xD;
           cytotoxicity against hepatoma cell lines. Interferon has been shown to normalise the&#xD;
           T-lymphocyte subpopullation and enhance the cytotoxic activity against an&#xD;
           HBsAg-producing hepatoma cell line in-vitro.&#xD;
&#xD;
        3. Interferon adverse effects&#xD;
&#xD;
           Interferon alpha-2b is registered for treatment of HCC and chronic hepatitis B in Hong&#xD;
           Kong. In patients with unresectable HCC, interferon has a much lower incidence of fatal&#xD;
           side-effects when compared to doxorubicin. Most patients experience flu-like symptoms&#xD;
           including fever, headache, fatigue and myalgia which usually subside spontaneously with&#xD;
           continuation of treatment. Less common but more serious adverse effects include&#xD;
           alopecia, leukopenia, thrombocytopenia, depression, irritability, and mental&#xD;
           deterioration. The adverse effects are dose-dependent and the majority are reversible&#xD;
           with a reduction in dosage. The use of high-dose interferon has been well-tolerated in&#xD;
           clinical trials involving patients with unresectable HCC.&#xD;
&#xD;
        4. Rationale&#xD;
&#xD;
      Interferon has anti-viral, anti-proliferative and immunodulatory activities. It has been used&#xD;
      clinically in the treatment of unresectable HCC as well as viral hepatitis B and C. It can&#xD;
      potentially reduce the incidence of recurrence due to residual tumour cells or metachronous&#xD;
      multicentric disease in patients after resection for HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of recurrent disease</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death of the patient</measure>
  </secondary_outcome>
  <enrollment>84</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alpha-2b</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients who undergo a curvative hepatic resection for HCC at the Department of&#xD;
        Surgery, Queen Mary Hospital are included. The criteria for curative resection include all&#xD;
        of the following :&#xD;
&#xD;
        i) Complete extirpation of disease as demonstrated by intraoperative ultrasonography during&#xD;
        surgery ii) Histologic evidence of a clear resection margin iii) No evidence of residual&#xD;
        disease in the liver remnant as demonstrated by spiral contrast-enhanced CT scan one month&#xD;
        after surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        i) patient refusal ii) age &gt; 75 years old iii) hospital mortality iv) disease previously&#xD;
        treated by regional or systemic chemotherapy, hormonal therapy or immunotherapy v) poor&#xD;
        hepatic function:&#xD;
&#xD;
          1. presence of hepatic encephalopathy&#xD;
&#xD;
          2. presence of ascites not controlled by diuretics&#xD;
&#xD;
          3. history of variceal bleeding within last 3 months&#xD;
&#xD;
          4. total serum bilirubin &gt; 50 umol/L&#xD;
&#xD;
          5. serum albumin &lt; 30 g/L&#xD;
&#xD;
          6. prothrombin time prolonged for &gt; 4 seconds vi) poor renal function with serum&#xD;
             creatinine &gt; 180ÔÅ≠mol/L vii) Absolute neutrophil count &lt; 1.5 x 109/L viii) Platelet&#xD;
             count &lt; 75 x 109/L ix) poor performance status with European Cooperative Oncology&#xD;
             Group (ECOG) scale grade III or IV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung Mau Lo, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, The University of Hong Kong</affiliation>
  </overall_official>
  <verification_date>October 2005</verification_date>
  <study_first_submitted>October 5, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>November 29, 2005</last_update_submitted>
  <last_update_submitted_qc>November 29, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2005</last_update_posted>
  <keyword>liver cancer</keyword>
  <keyword>hepatectomy</keyword>
  <keyword>survival</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

